Get alerts for new trials in your area by subscribing now
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
for
Juvenile Psoriatic Arthritis
Location: Chicago IL, Portland OR, El Paso TX
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 2 - 17
Code: NCT06751238
Phase1, Recruiting
Transition to Adulthood Through Coaching and Empowerment in Rheumatology